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To the Editor:
The impact of thyroid deficiency and its reversal by T4
replacement therapy on glucose metabolism remained
controversial [1–4]. Small doses of thyroxine (1 mg/kg) nor-
malized most of the intermediary metabolic parameters of
thyroidectomized rats [5], while 20-times-higher doses
would be needed to depress the high rates of thyroid-
stimulating hormone (TSH) release of pituitary via feed-
back inhibition [6]. Thyroxine levels can be brought up to
normal with oral thyroxine pills from 25 to 200 mg/day.
Under constant balanced conditions, low levels of thyroid
hormones maintain normal intermediary metabolism;
insufficient thyroxine administration results in hypo-
thyroidism; and high thyroxine doses cause swinging to
hyperthyreoidic symptoms. The regulatory functions of
adenohypophysis and pituitary-dependent glands are to
smooth out oscillations. In thyroidectomized patients, the
negative feedback loop does not function, and the devel-
opment of hypothyreoidic symptoms are prevented by
thyroxine replacement therapy.
This letter presents a hypothyroid case where the muscu-
lar side effects following thyroxine replacement therapy
manifested as muscle pain. Long-term protection against
thyroxine replacement therapy-induced muscle pain has
been provided by low doses (2 g/day) of creatine mono-
hydrate administration.
In 1993, our male patient was 49 years old when his
hyperthyreosis was diagnosed. In 2001, the patient had
7–8 kg loss in weight in 6 months and hyperthyreosis
recidivawas diagnosed. A single dose of p.o. administered
radioisotope 131I (240 MBq) was applied in a capsular form.
Three months later (December 2001), laboratory param-
eters showed high creatine kinase (894 U/L) and transami-
nase (GOT 65 IU/L, GPT 61 IU/L) activities. Elevated
creatine kinase levels may reflect injury in myocardial inf-
arction, muscle breakdown, muscular dystrophy, myositis,
reduced adenosine triphosphate (ATP) level in muscle, and
acute renal failure. Upon the radioactive destruction of
thyroid function, the patient experienced excessive muscle
pain and involuntary defecation of stool for several days.
The urinary incontinence was even more distressing and
lasted for several weeks. The repeated laboratory test
(January 2002) showed high creatine kinase activity
(478 U/L), while transaminase activities returned to normal.
Hypothyroid symptoms were temporarily compensated by
thyroid hormone substitution (50 mg L thyroxine/day) to
the euthyreotic state (T4: 91.9 nmol/L; normal values:
58–154 nmol/L; TSH: 1.5 U/L; normal values: 0.3–3 U/L).
In May 2002, the patient complained of cramps in legs and
scapular arches accompanied by the inability to raise his
hands and legs. Neurological examinations in the lower
limbs and in the shoulder indicated strain and tenderness.
Neurophysiology confirmed mild diffuse myelin damage in
the motor fibers of the lower limbs, median neuropathy of
the wrist (carpal tunnel syndrome) with paresthesias,
numbness, andmuscleweakness in the hand. Electromyo-
graphy showed resting electrical potential in these
muscles. In August 2002, scintigraphic visualization of the
thyroid gland could not be performed due to the low
radioisotope 131I uptake. Ultrasound analysis showed an
inhomogeneous thyroid gland with somewhat smaller
lobes. Hormonal levels (TSH: 16.4 U/L, T4: 5.8 pmole/L,
T3:1.4 nmole/L) indicated hypothyreosis factitia, which
culminated at ~50 U/L TSH level. Under these hypothy-
reotic developments, neither degenerative spinal, nor car-
diological, nor electrophysiological alterations could be
detected. To compensate hypothyreosis, the thyroxine
dose was raised from daily 50 to 75 and then to 100 mg
L-thyroxine, which, however, aggravated the painful
muscle symptoms without reaching the euthyroid state.
The extremely painful muscle cramps, 1–2 hours after
taking 50 mg of T4, forced the patient to refuse the
increase of thyroxine dose. After each thyroxine adminis-
tration, muscle pain and extreme muscle weakness devel-
oped and lasted for several days. By day 4 and 5 after
thyroxine administration, the stinging pain numbed his
fingers and hands. As a pain reliever, daily one tablet of
Rheosolon (100 mg phenylbutazone, 2 mg prednisolone;
Rheosolon, Pannonpharma Kft, Pecs, Hungary) was
administered. The anti-inflammatory prednisolone induced
an aggressive behavior and hostile manner of the patient
diagnosed as steroid “roid” rage. To avoid the corticoster-
oid side effects, its use was suspended.
The patient was given temporarily L-carnitine (2 g/day) as
a nutrition supplement to generate metabolic energy and
to inhibit the accumulation of lactic acid in the muscle.
Although the termination of prednisolone therapy ceased
the steroid rage and improved the mental state, carnitine
administration had no significant effect on muscle function
and pain. The therapy was then switched from carnitine
to creatine monohydrate. Creatine, a muscle-building
supplement, is taken for loading in high doses (20–25 g/
day) and in small doses (2.5–5 g/day) for maintenance.
Creatine kinase catalyzes the conversion of creatine to
creatine phosphate in the muscle. Phosphocreatine as an
energy reservoir converts adenosine diphosphate to ATP.
The daily creatine requirement is 2 g, half of it is produced
by the organism, and the other half is ingested with meat.
Our patient was administered creatine monohydrate to
overcome the muscle pain of high-intensity initial tremor
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and muscle cramps that followed thyroxine intake. Creat-
ine administration turned out to be a tolerable and efficient
treatment after T4 induced muscle pain. The recent
regime of hypothyroidism treatment involves p.o. admin-
istration of 50 mg of L-thyroxine (7:00 AM). To reduce and
to eliminate other potential side effects, the patient took
an initial 5 g of creatine monohydrate p.o. (8:30 AM) for 1
year, which was reduced to 2 g creatine monohydrate.
The second dose (50 mg) of L-thyroxine is taken without
creatine administration (4:00 PM). The patient is pain-free
for 2.5 years, proving the efficiency of the treatment of
muscular side effects caused by the thyroxine replace-
ment therapy.
There is much debate about the dose of thyroxine
replacement therapy and whether the suppression of the
serum TSH concentration is a risk factor for osteoporosis
[7]. It is also doubted whether the so-called replacement
therapy of thyroxine could suppress the secretion of TSH.
To achieve this goal, high thyroxine doses could lead to
serious cardiac complications, such as atrial fibrillation,
cardiomyopathy, and focal myocarditis [8], and even to
life-threatening ventricular fibrillation [9].
The effects of thyroxine replacement therapy in patients
with hypothyroidism [10] are in conformity with animal
experiments, which provided evidence that after thyroxine
administration, glycogenolysis predominates over glyco-
gen synthesis [11]. However, the long-term replacement
therapy could have exhausted the muscle glycogen stores
of our patient. The ATP shortage in the hypoxic muscle
was at least temporarily alleviated by creatine administra-
tion. Creatine addition seems to be justified under inter-
mittent hypoxic-normoxic exposures characterized by the
decrease of the muscular contents of creatine phosphate,
citrate, alpha-ketoglutarate, and glutamate [12]. Creatine
supplementation can be especially useful in the hypothy-
roidic muscle when the mitochondrial functions are ham-
pered. That thyroid ablation induces a decrease in muscle
mitochondrial oxygen consumption and can be reversed
by thyroxine was proved in hypothyroid rats [13]. The
depletion of citrate and the retarded mitochondrial func-
tion in muscle under hypoxic conditions are shown in
Figure 1.
Moreover, thyroxine treatment stimulates the breakdown
of glycogen and glycogenic amino acids into glucose.
Under hypoxic conditions, lactate production (net gain 2
ATP) causes pain in muscle. Lactate carried to the liver by
the blood is converted back to glucose through gluconeo-
genesis in a quite expensive (6 ATP) manner (Figure 2).
Creatine is converted to creatine phosphate and stored
(>90%) in the skeletal muscle. In the healthy muscle,
supplementary ATP production comes from the conver-
sion of phosphocreatine to creatine catalyzed by the cre-
atine kinase, and at maximal exercise, the main source of
ATP in oxidative (type I) muscle fibers is oxidative phos-
phorylation [14]. In hypothyroid state when anaerobic gly-
colysis plays a significant role, the inadequate ATP
production in the mitochondria of muscle cells is supple-
mented by a higher creatine kinase activity as manifested
in our patient. Inadequate ATP production in mitochondria
was indicated by the supplementary substrate level phos-
phorylation observed in our patient by the elevated cre-
atine kinase activity. That creatine may improve muscle
strength was demonstrated in muscular dystrophies [15].
Other studies also indicate that creatine supplementation
is beneficial for skeletal muscle function in the McArdle
glycogen storage disease [16] and provides a safe, effec-
tive, and inexpensive treatment in inflammatory myopa-
thies [17]. The side effects of low doses of creatine either
could not be traced or were negligible [18,19]. The long-
term use of moderate doses of creatine (14 g/day for 3
years) was described to be safe [20]. Creatine was
reported to have a protective effect on the heart, muscle,
and neurological diseases by reducing significantly the
cholesterol level [21,22]. One report described indivi-
duals suffering from kidney problems after using creatine
[23], giving a warning that further studies are necessary
to demonstrate the protective and adverse effects of
creatine.
The observation that high-dose creatine treatment wors-
ened the main clinical symptoms of exercise intolerance in
McArdle disease prompted investigations to clarify the
effective creatine dose without adverse effects, which
limited it between 60 and 150 mg/kg daily [24]. The same
Figure 1 Lipogenic pathway under hypothyroid
state in hypoxic muscle cell. In the mitochondria of a
hypoxic muscle cell, the citrate cycle, the terminal
oxidation, and oxidative phosphorylation are
retarded. In the absence of normal aerobic condi-
tions, the overproduction of acetyl-CoA induces
fatty acid and lipid synthesis in the liver and adi-
pose tissue. Glu = glucose; AcCoA = acetyl-CoA;
Cit = citrate; CL = citrate lyase; Pyr = pyruvate;
OxAc = oxaloacetate; Mal = malate; MalCoA =
malonylCoA; FA = fatty acid.
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authors confirmed that high-dose creatine increased
muscle pain in this glycogen storage disease type V [25].
These findings are in conformity with the observations of
others that creatine improved muscle strength in exercis-
ing healthy individuals and in patients with neuromuscular
disease and heart failure, but did not improve pulmonary
rehabilitation [26]. There was a mild, but significant,
improvement in muscle strength and daily activities also in
muscular dystrophies [27]. Creatine was well-tolerated in
myotonic dystrophy without clinically relevant side effects,
but did not result in significant improvement of muscle
strength or daily life activities [28].
Finally, to safely use creatine without any doubt, it should
be taken only in low doses. People with low creatine levels
(e.g., vegetarians) seem to benefit more by taking creatine
supplements than those who have higher levels of creat-
ine. The saturation level can be reached within a few days
by taking an initial higher (5 g/per day) loading dose to
relieve muscle pain, followed by a lower (2 g/day) mainte-
nance dose as we have recommended to our patient.
The effects of thyroxine replacement therapy on patients
with hypothyroidism [10] are in conformity with animal
experiments, which provided evidence that in thyroxine
administration, glycogenolysis predominates over glyco-
gen synthesis [11], leading to the exhaustion of the stored
energy. The inadequate amount of chemical energy of ATP
in muscular mitochondria was indicated by the supple-
mentary substrate level phosphorylation manifested by
the elevated creatine kinase activity of our patient. ATP
shortage in the hypoxic muscle can be at least temporarily
alleviated by creatine administration, which was stored
(>90%) in the skeletal muscle. Based on this case study,
creatine seems to be a useful energy supplement in
hypothyroidism when the mitochondrial functions in the
hypoxic muscle are retarded.
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